ReviewFrontiers in immunology2026
HMC3 revealed: how much do these "Microglia" really tell us?
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microglia are a key driver of neurodegenerative disease, orchestrating inflammatory signaling, metabolic stress responses, synaptic remodeling, and neuronal fate within the central nervous system (CNS). Among experimental models, the human microglial cell line, HMC3, is one of the most widely used models for mechanistic investigation and pharmacological screening of microglial dysfunction, particularly in neurodegenerative contexts. Nevertheless, a key question remains: how faithfully does HMC3 reflect human microglial biology? This review integrates current evidence on HMC3 cells, including their molecular and metabolic features, functional plasticity, and disease-oriented applications. HMC3 cells reproduce hallmark neurodegeneration-associated programs, such as stimulus-dependent polarization, oxidative and endoplasmic reticulum stress signaling, inflammasome activation, autophagy dysregulation, lipid remodeling, angiogenic cross-talk, and phagocytic clearance of amyloid and apoptotic debris, modeling processes relevant to Alzheimer's disease, Parkinson's disease, ischemic injury, and metabolic neurodegeneration. Neuron-microglia co-culture systems further demonstrate the direct impacts of HMC3 activation states on neuronal vulnerability and survival. We also summarize the expanding repertoire of pharmacological and genetic interventions applied to HMC3, highlighting their compatibility with high-throughput and multi-omics discovery platforms. Despite inherent limitations of immortalized models, HMC3 represents a powerful front-line tool for dissecting neurodegenerative microglial mechanisms and steering early therapeutic discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.